Collagen alpha-1(XVIII) chain C-terminal fragment (Endostatin) (Endostatin)

Endostatin is a 20 kDa C-terminal proteolytic fragment derived from domain NC1 of collagen XVIII, part of the extracellular matrix. It serves as a potent endogenous inhibitor of angiogenesis, primarily by suppressing the proliferation, migration, and survival of endothelial cells through binding to multiple cell-surface receptors and interrupting key signaling pathways required for new blood vessel formation. This activity has made endostatin a target for anti-tumor therapies, showing strong efficacy in animal models, though less robust effectiveness and the need for high dosages in human clinical trials. It interacts with several extracellular matrix components and cell surface proteins, highlighting its role as a modulator of cell-matrix communication rather than a classic receptor, enzyme, or transporter target. Endostatin's low toxicity but complex pharmacology makes it therapeutically appealing but also challenging in terms of achieving sufficient efficacy and delivery[1][2][3][4][5][6][7].

Other names

EndostatinCollagen XVIII-derived endostatinC-terminal domain NC1 of collagen XVIIICollagen alpha-1(XVIII) chain C-terminal fragment[6][7]

Direct binding to endothelial cell surface receptors (heparan sulfate proteoglycans, integrins, nucleolin, matrix metalloproteinases, glypicans, tropomyosin, laminin-1) Inhibits signals required for angiogenesis and endothelial cell survival/proliferation May activate downstream tyrosine kinase signaling pathways and alter gene expression in target cells[3][4]